The Aptus Pharma IPO opening date is September 23, 2025, and closing date is September 25, 2025. The Aptus Pharma IPO is a book-built issue. The company will raise approximately ₹13.02 crore through the IPO, consisting of fresh shares worth ₹13.02 crore and equity shares with a face value of ₹10.
The Aptus Pharma IPO price band is ₹65 to ₹70 per share. The retail share is 35%, QIBs 50%, and HNIs 15%. The Aptus Pharma IPO will be listed on the BSE on September 30, 2025. The allotment date for the Aptus Pharma IPO is September 26, 2025.
The company reported revenue of ₹24.64 crore in 2025, compared to ₹17.88 crore in 2024. The company reported a profit of ₹3.10 crore in 2025, compared to ₹0.80 crore in 2024. Based on the financials, IPO investors should invest in the IPO GMP for the long term.
Aptus Pharma IPO Details
| IPO Date | September 23, 2025 to September 25, 2025 |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Issue Price Band | ₹65 to ₹70 per share |
| Lot Size | 2,000 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 18,60,000 shares (aggregating up to ₹13.02 Cr) |
| Reserved for Market Maker | 94,000 shares Market-Hub Stock Broking Pvt.Ltd. |
| Net Offered to Public | 17,66,000 shares (aggregating up to ₹12.36 Cr) |
| Issue Type | Book building IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 50,00,000 shares |
| Share Holding Post Issue | 68,60,000 shares |
Aptus Pharma Limited Financial Information (Restated)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 21.92 | 10.03 | 6.22 |
| Total Income | 24.64 | 17.88 | 13.90 |
| Profit After Tax | 3.10 | 0.80 | 0.19 |
| EBITDA | 4.76 | 1.49 | 0.57 |
| Net Worth | 6.97 | 1.77 | 0.97 |
| Reserves and Surplus | 1.97 | 1.47 | 0.67 |
| Total Borrowing | 10.36 | 5.31 | 2.21 |
| Amount in ₹ Crore | |||
Aptus Pharma IPO Market Lot
The Aptus Pharma IPO minimum market lot is 4,000 shares with ₹2,80,000 application amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 4,000 | ₹2,80,000 |
| Retail Maximum | 2 | 4,000 | ₹2,80,000 |
| S-HNI Minimum | 3 | 6,000 | ₹4,20,000 |
| S-HNI Maximum | 7 | 14,000 | ₹9,80,000 |
| B-HNI Minimum | 8 | 16,000 | ₹11,20,000 |
IPO Reservation
| Investor Category | Share Offered | % Shares |
| Market Maker Shares Offered | 94,000 Shares | 5.05% |
| QIB Shares Offered | 8,80,000 Shares | 47.31% |
| Anchor Investor | 5,28,000 Shares | 28.39% |
| QIB (Ex. Anchor) | 3,52,000 Shares | 18.92% |
| NII Shares Offered | 2,66,000 Shares | 14.30% |
| bNII > ₹10L | – Shares | -% |
| sNII < ₹10L | – Shares | -% |
| Retail Shares Offered | 6,20,000 Shares | 33.33% |
Aptus Pharma IPO Anchor Investors
| Anchor Bidding Date | September 22, 2025 |
| Anchor Investors List | / |
| Shares Offered | 5,28,000 Shares |
| Anchor Size | 3.70 Cr. |
| lock-in period end date 50% shares (30 Days) | October 26, 2025 |
| lock-in period end date 50% shares (90 Days) | December 25, 2025 |
Aptus Pharma IPO Dates
The Aptus Pharma IPO date is September 23 and the close date is September 25. The Aptus Pharma IPO allotment will be finalized on September 26 and the IPO listing on September 30.
| IPO Open Date: | September 23, 2025 |
| IPO Close Date: | September 25, 2025 |
| Basis of Allotment: | September 26, 2025 |
| Refunds: | September 29, 2025 |
| Credit to Demat Account: | September 29, 2025 |
| IPO Listing Date: | September 30, 2025 |
| IPO Bidding Cut-off Time: | September 25, 2025 – 5 PM |
Promoters and Holding Pattern
The promoters of the company are Tejash Maheshchandra Hathi, Chatrabhuj Vallabhbhai Butani, Kapilbhai Hasmukhbhai Chandarana, Ghanshyam Vinubhai Pansuriya, Milly Chetan Lalseta, Riddhish Natwarlal Tanna, Gaurang Rameshchandra Thakker, Kripaliben Mayank Thakker And Kunjal Piyushbhai Unadkat.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 50,00,000 | 100% |
| Promoter Holding Post Issue | 68,60,000 | 72.89% |
Objects of the Issue & Utilisation of proceeds
| Purpose | Crores | % |
| Capital Expenditure for Office Premises with furniture and Industrial Racks | 1.63 | -% |
| Working Capital | 8.00 | -% |
| General Corporate Purpose | – | -% |
Aptus Pharma IPO Valuation – FY2025
Check Aptus Pharma IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 44.50% |
| ROCE: | 45.66% |
| EBITDA Margin: | 19.31% |
| PAT Margin: | -% |
| Debt to equity ratio: | 1.49 |
| Earning Per Share (EPS): | ₹6.37 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 44.50% |
| Net Asset Value (NAV): | ₹13.93 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Zota health care limited | 3.16 | 382.12 | 2.72 | 110.83 | 261.90 Cr. |
| Sunrest Lifescience Limited | 4.66 | 10.56 | 12.36 | 37.72 | 33.12 Cr. |
| Lincoln Pharmaceuticals Limited | 41.11 | 13.53 | 12.26 | 335.34 | 645.71 Cr. |
About Aptus Pharma IPO
Aptus Pharma is one of the leading companies in the marketing and sale of pharmaceutical products. The company does not have its own factories but instead sources products through contract manufacturers.
The company offers a wide range of pharmaceutical products across various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuropsychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general health products. The company works with a wide range of healthcare professionals from various fields, including general physicians, pediatricians, women's health specialists, cardiologists, diabetologists, neurologists, etc.
The company has multiple promoters, including Mr. Tejash Maheshchandra Hathi, who has over 20 years of experience in the pharmaceutical industry.